SAMe 400 mg

SAMe 400 mg

Life Extension4.8 (3,799 ratings)
Format:Tablet Quantity: 60 Tablet(s) · 60 servings
Goals
$37.49 $0.62 per serving
AmazonLowest$37.49iHerb$52.50Pure Formulas$52.50

About this product

The one-tablet serving supplies a full-strength SAMe amount for mood, joint, stress, or methylation support. Enteric coating helps protect the ingredient through the stomach.

The exact stabilizing salt is not named, and the label does not distinguish net SAMe from total ingredient weight. Those omissions prevent a complete quality assessment.

The longer supply and low cost support sustained use. Safety considerations remain important because SAMe has medication and mood-state interactions.

Who is it for
  • Adults seeking full-strength enteric SAMe
  • Users planning sustained mood or joint support
  • Value-focused one-tablet users
Best for
  • Protected intestinal delivery
  • Full-strength daily use
  • Strong long-term value

Pros

  • Enteric-coated tablet
  • Full commonly used amount
  • One-tablet serving
  • Excellent practical value

Cons

  • SAMe salt is unspecified
  • Net active yield is unclear
  • Moisture packaging is not described
  • Single active covers a narrow pathway

Warnings

  • SAMe may provoke mania in people with bipolar disorder
  • Combining SAMe with serotonergic antidepressants, MAO inhibitors, or triptans may raise serotonin-syndrome risk
  • SAMe can cause anxiety, insomnia, nausea, or diarrhea

Product analysis

84 out of 100
A high-value full-dose enteric tablet with strong delivery design, though salt identity and active yield are unclear.

AI assessment of the formula, label and price. How scoring works

Nutrient quality90

Enteric coating supports delivery beyond the stomach, but a stabilized salt is not identified. A full commonly used amount provides strong active depth, although net SAMe yield remains unclear.

Ingredient transparency79

The active amount is disclosed without a hidden blend. Missing net active yield, complete directions, and non-active ingredients leave important gaps.

Customer satisfaction72

The supplied average rating is very strong and the rating volume is substantial. No specific experience details were provided to judge repeated complaints or purpose alignment.

Value for money94

Ingredient quality and serving economics support strong practical value. It compares favorably within the category despite remaining disclosure gaps.

Format
Tablet
Container
60 Tablet(s)
Per serving
$0.62
Also available
SAMe 400 mgSAMe 400 mg • 30 Tablet(s) • 30 servings$27.00
Customer rating
4.8 · 3,799 ratings
Report analysis

Goals

Mood Support
Mood Support
Impact
Moderate effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg
Study evidence
SAMe Disputed 20 studies
Joint Health
Joint Health
Impact
High effect
B- Ingredient FitF PathwaysB+ EvidenceA+ Formulation Logic
SAMe · 400 mg
Study evidence
SAMe Supportive 9 studies
Detoxification
Detoxification
Impact
Highest effect
A Ingredient FitC- PathwaysA- EvidenceA+ Formulation Logic
SAMe · 400 mg
Study evidence
SAMe Supportive 30 studies
Stress Relief
Stress Relief
Impact
High effect
B- Ingredient FitF PathwaysC+ EvidenceA+ Formulation Logic
SAMe · 400 mg
Study evidence
SAMe Not classified

No linked studies yet.

Ingredients

IngredientAmount per servingScore
S-Adenosyl-Methionine
400 mg 44
Adults 18–50
Report overview
SAMe · 400 mg OverallScore44
F Active Ingredient Quality & BioavailabilityB- Dose, Safety & Label TransparencyD- Value
The label lists 400 mg of SAMe per serving, but the saved facts do not identify a stabilizing salt, net active-ion amount, blister pack, or release coating. The stated ingredient amount is clear, while those stability and yield details remain unknown. Cost is low relative to the reference amount.
How this ingredient is rated

Active Ingredient Quality & Bioavailability17

The saved facts do not identify a stabilizing salt or individual blister packaging.
Stabilized Salt Form
The saved facts do not specify a stabilizing salt form for the SAMe.
Packaging Integrity
No individual blister-pack claim is recorded, so the packaging type remains unclear.

Dose, Safety & Label Transparency72

The label states 400 mg, but does not separate net active SAMe from the salt-complex weight.
Active Dosage Strength
The label lists 400 mg of SAMe per serving, matching the collection's median amount.
Net SAMe Yield Transparency
Only one SAMe amount is listed, so salt-complex weight and net active SAMe are not distinguished.

Value40

The listed price is low, but no release-protection claim is recorded.
Price Per 400mg Active Dose
The normalized price is low, but no enteric or delayed-release claim is recorded.
View ingredientView products
Loading alternative details
85 Performance

SAMe 400 mg

Lake Avenue Nutrition

A stabilized salt and enteric coating protect a full SAMe amount during storage and passage through the stomach. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Net active yield and moisture-resistant packaging remain unclear.

84 Performance

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt supplies a full SAMe amount in one tablet. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. Enteric and sealed moisture protection are not stated, and net active yield remains unclear.

79 Performance

SAMe 400 mg

Source Naturals

Enteric coating protects a full SAMe amount from stomach acid. Its balance of dose, stabilization, or gastric protection is stronger than less protected eligible formulas. The stabilized salt, net active yield, and moisture protection are not identified.

74 Budget

SAMe 200

Jarrow Formulas

A common starting SAMe amount provides a simple, low-cost option. It lowers routine cost versus the original. Neither a stabilized salt nor acid-resistant delivery is identified, so protected active yield is uncertain.

83 Budget

SAMe 200 mg

NOW

A stabilized disulfate tosylate salt provides a credible common starting amount at efficient routine value. It lowers routine cost versus the original. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

84 Budget

SAMe 400 mg

Nutricost

A stabilized salt provides a full SAMe amount with efficient dose value. It lowers routine cost versus the original. The two-capsule serving has no stated acid resistance, and moisture protection is unclear.

84 Value

SAMe 400 mg

NOW

A stabilized disulfate tosylate salt provides a full SAMe amount with favorable dose value. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection and sealed moisture protection are not stated.

80 Value

SAMe 400 mg

Swanson

A stable disulfate tosylate form provides a full SAMe amount in one tablet. Compared with the original, its delivery design and routine economics offer a useful value trade-off. Enteric protection, net active yield, and moisture-resistant packaging are not stated.

78 Value

SAMe 200 mg S-Adenosyl-Methionine

Life Extension

Enteric coating protects a common starting SAMe amount from stomach acid. Compared with the original, its delivery design and routine economics offer a useful value trade-off. The salt form, net active yield, and moisture protection are not identified.

Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
    Guo T; Chang L; Xiao Y; Liu Q · PloS one · 2015
    Meta-analysis705 participants11 studies pooledDetoxification forSAMe
  2. S-Adenosylmethionine (SAMe) as an adjuvant therapy for patients with depression: An updated systematic review and meta-analysis.
    Peng TR; Cheng HY; Wu TW · General hospital psychiatry · 2024
    Meta-analysis1,522 participants14 studies pooledMood Support forSAMe
  3. S-Adenosylmethionine for osteoarthritis of the knee or hip.
    Rutjes AW; Nüesch E; Reichenbach S; Jüni P · The Cochrane database of systematic reviews · 2010
    Meta-analysis656 participants4 studies pooledJoint Health forSAMe
  4. S-adenosyl-L-methionine treatment for alcoholic liver disease: a double-blinded, randomized, placebo-controlled trial.
    Medici V; Virata MC; Peerson JM; Stabler SP; French SW; Gregory JF; Albanese A; Bowlus CL; Devaraj S; Panacek EA; Richards JR; Halsted CH · Alcoholism, clinical and experimental research · 2012
    Randomized trial37 participantsDetoxification forSAMe
  5. Safety and efficacy of S-adenosylmethionine (SAMe) for osteoarthritis.
    Soeken KL; Lee WL; Bausell RB; Agelli M; Berman BM · The Journal of family practice · 2002
    Meta-analysis11 studies pooledJoint Health forSAMe
  6. Efficacy and acceptability of S-adenosyl-L-methionine (SAMe) for depressed patients: A systematic review and meta- analysis.
    Limveeraprajak N; Nakhawatchana S; Visukamol A; Siripakkaphant C; Suttajit S; Srisurapanont M · Progress in neuro-psychopharmacology & biological psychiatry · 2024
    Meta-analysis2,183 participants23 studies pooledMood Support forSAMe
  7. Efficacy of S-adenosyl-L-methionine in speeding the onset of action of imipramine.
    Berlanga C; Ortega-Soto HA; Ontiveros M; Senties H · Psychiatry research · 1993
    Single-arm trial40 participantsMood Support forSAMe
  8. S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
    Najm WI; Reinsch S; Hoehler F; Tobis JS; Harvey PW · BMC musculoskeletal disorders · 2004
    Randomized trial61 participantsJoint Health forSAMe
  9. Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
    Noureddin M; Sander-Struckmeier S; Mato JM · World journal of hepatology · 2020
    Systematic review9 studies pooledDetoxification forSAMe
  10. Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
    Delle Chiaie R; Pancheri P; Scapicchio P · The American journal of clinical nutrition · 2002
    Randomized trial576 participantsMood Support forSAMe
  11. Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
    Zhang L; Liu XH; Qi HB; Li Z; Fu XD; Chen L; Shao Y · European review for medical and pharmacological sciences · 2016
    Randomized trial120 participantsDetoxification forSAMe
  12. Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
    Caruso I; Pietrogrande V · The American journal of medicine · 1988
    Clinical trial734 participantsJoint Health forSAMe
  13. A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
    Pancheri P; Scapicchio P; Chiaie RD · The international journal of neuropsychopharmacology · 2004
    Randomized trial293 participantsMood Support forSAMe
  14. A randomised controlled trial of ursodeoxycholic acid and S-adenosyl-l-methionine in the treatment of gestational cholestasis.
    Roncaglia N; Locatelli A; Arreghini A; Assi F; Cameroni I; Pezzullo JC; Ghidini A · BJOG : an international journal of obstetrics and gynaecology · 2004
    Randomized trial46 participantsDetoxification forSAMe
  15. Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
    Glorioso S; Todesco S; Mazzi A; Marcolongo R; Giordano M; Colombo B; Cherie-Ligniere G; Mattara L; Leardini G; Passeri M · International journal of clinical pharmacology research · 1985
    Randomized trial150 participantsJoint Health forSAMe
  16. Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.
    Sarris J; Murphy J; Mischoulon D; Papakostas GI; Fava M; Berk M; Ng CH · The American journal of psychiatry · 2017
    Meta-analysisMood Support forSAMe
  17. Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
    Liu GY; Wang W; Jia WD; Xu GL; Ma JL; Ge YS; Yu JH; Sun QK; Meng FL · World journal of surgical oncology · 2014
    Non-randomized trial81 participantsDetoxification forSAMe
  18. A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
    König B · The American journal of medicine · 1988
    Single-arm trial108 participantsJoint Health forSAMe
  19. Interventions for treating cholestasis in pregnancy.
    Burrows RF; Clavisi O; Burrows E · The Cochrane database of systematic reviews · 2002
    Systematic review227 participants9 studies pooledDetoxification forSAMe
  20. S-adenosylmethionine blood levels in major depression: changes with drug treatment.
    Bell KM; Potkin SG; Carreon D; Plon L · Acta neurologica Scandinavica. Supplementum · 1994
    Randomized trial26 participantsMood Support forSAMe
  21. Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
    Hosea Blewett HJ · Critical reviews in food science and nutrition · 2008
    Narrative reviewJoint Health forSAMe
  22. S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
    Mato JM; Cámara J; Fernández de Paz J; Caballería L; Coll S; Caballero A; García-Buey L; Beltrán J; Benita V; Caballería J; Solà R; Moreno-Otero R; Barrao F; Martín-Duce A; Correa JA; Parés A; Barrao E; García-Magaz I; Puerta JL; Moreno J; Boissard G; Ortiz P; Rodés J · Journal of hepatology · 1999
    Randomized trial123 participantsDetoxification forSAMe
  23. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review.
    Williams AL; Girard C; Jui D; Sabina A; Katz DL · Clinical and investigative medicine. Medecine clinique et experimentale · 2005
    Meta-analysisMood Support forSAMe
  24. A double-blind trial of ademetionine vs naproxen in activated gonarthrosis.
    Domljan Z; Vrhovac B; Dürrigl T; Pucar I · International journal of clinical pharmacology, therapy, and toxicology · 1989
    Non-randomized trial20 participantsJoint Health forSAMe
  25. Beneficial effects of S-adenosyl-L-methionine on post-hepatectomy residual liver function: a prospective, randomized, controlled clinical trial.
    Su ZR; Cui ZL; Ma JL; Li JS; Ge YS; Yu JH; Pan JH; Xu GL; Jia WD · Hepato-gastroenterology · 2014
    Randomized trial79 participantsDetoxification forSAMe
  26. S-adenosylmethionine treatment of depression: a controlled clinical trial.
    Bell KM; Plon L; Bunney WE; Potkin SG · The American journal of psychiatry · 1988
    Non-randomized trial18 participantsMood Support forSAMe
  27. Treatment of knee osteoarthritis.
    Ringdahl E; Pandit S · American family physician · 2011
    Narrative reviewJoint Health forSAMe
  28. Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease.
    Ivashkin VT; Maevskaya MV; Kobalava ZD; Uspenskiy YP; Fominih JA; Rozanov AV; Tolkacheva VV; Sotnikova TI; Alikhanov BA; Gorbacheva IA; Ershova OB; Znakhyrenko AA; Sokolov KA; Sander-Struckmeier S · Minerva gastroenterologica e dietologica · 2019
    Single-arm trial72 participantsDetoxification forSAMe
  29. A comprehensive review on the efficacy of S-Adenosyl-L-methionine in Major Depressive Disorder.
    De Berardis D; Orsolini L; Serroni N; Girinelli G; Iasevoli F; Tomasetti C; de Bartolomeis A; Mazza M; Valchera A; Fornaro M; Perna G; Piersanti M; Di Nicola M; Cavuto M; Martinotti G; Di Giannantonio M · CNS & neurological disorders drug targets · 2016
    Narrative reviewMood Support forSAMe
  30. Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
    Di Pierro F; Settembre R · International journal of general medicine · 2015
    Randomized trial64 participantsMood Support forSAMe